Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

A larger waist circumference is associated with a higher risk of all-cause mortality and decreased life expectancy. Meanwhile ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Tesla Shares in electric vehicle maker Tesla have climbed back to their highest point since February, amid investor optimism ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...